Anzeige
Mehr »
Freitag, 05.09.2025 - Börsentäglich über 12.000 News
SuperBuzz x Prymatica: Ein Vertriebsdeal, der KI-Hype in B2B-Umsätze verwandeln könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P8F1 | ISIN: CA74764Y2050 | Ticker-Symbol: 0K91
Tradegate
05.09.25 | 15:04
12,800 Euro
+4,92 % +0,600
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
QUANTUM BIOPHARMA LTD Chart 1 Jahr
5-Tage-Chart
QUANTUM BIOPHARMA LTD 5-Tage-Chart
RealtimeGeldBriefZeit
11,90012,10017:41
11,70012,10017:25

Aktuelle News zur QUANTUM BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
QUANTUM BIOPHARMA Aktie jetzt für 0€ handeln
21.08.Quantum Biopharma Ltd: Quantum Biopharma board OKs $26K (U.S.) debt settlement10
21.08.Quantum BioPharma Announces Corporate Updates151TORONTO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated...
► Artikel lesen
21.08.Quantum Biopharma Ltd. - 6-K, Report of foreign issuer3
12.08.Quantum Biopharma Ltd: Quantum Biopharma to seek shareholder OK for financing9
12.08.Quantum BioPharma to seek shareholder approval for private placement4
12.08.Quantum BioPharma Ltd.: Quantum BioPharma Announces Update to Previously Announced Private Placement473Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to...
► Artikel lesen
11.08.Quantum Biopharma Ltd: Quantum Biopharma signs agreement with manufacturer4
11.08.Quantum BioPharma schließt Produktionsvertrag für MS-Medikament in oraler Form6
11.08.Quantum BioPharma signs manufacturing deal for MS drug oral form4
11.08.Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial156TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated...
► Artikel lesen
08.08.Quantum Biopharma Ltd: Quantum Biopharma talks PET tracer in MS study4
08.08.Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients8
08.08.Quantum Biopharma Ltd. - 6-K, Report of foreign issuer3
07.08.Quantum BioPharma GAAP EPS of -$3.2312
07.08.Quantum BioPharma reports strong Q2 with increased assets, no debt3
07.08.Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 ...216TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce its financial and operational...
► Artikel lesen
06.08.Quantum Biopharma Ltd: Quantum Biopharma receives Lucid-MS study report5
05.08.Quantum Biopharma Reports Positive Phase 1 Safety For Multiple Sclerosis Drug7
05.08.Quantum BioPharma stock falls after clinical trial report release4
05.08.Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)222TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a...
► Artikel lesen
Weiter >>
146 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,4